Danielle Mankin
Family Medicine · Savannah, GANPI 1770831588
Payments from drug & device makers
Across 291 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$722
- AbbVie$522
- Lilly USA, LLC$382
- AstraZeneca$369
- Novartis$273
- GSK$262
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,959100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $722 |
| AbbVie(2 entities) | 37 | $522 |
| Lilly USA, LLC | 25 | $382 |
| AstraZeneca | 20 | $369 |
| Novartis | 13 | $273 |
| GSK | 15 | $262 |
| Amgen | 17 | $260 |
| Pfizer | 10 | $204 |
| Johnson & Johnson | 14 | $192 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $178 |
| Ferring Pharmaceuticals Inc. | 9 | $165 |
| Otsuka America Pharmaceutical, Inc. | 6 | $148 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $116 |
| Insulet Corporation | 5 | $104 |
| Abbott | 5 | $97 |
| Sanofi Pasteur Inc. | 5 | $89 |
| Merck | 6 | $85 |
| E.r. Squibb & Sons, L.L.C. | 5 | $75 |
| Biohaven Pharmaceuticals, Inc. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Boston Scientific | 2 | $68 |
| Idorsia Pharmaceuticals US Inc | 4 | $58 |
| Boehringer Ingelheim | 3 | $49 |
| Vertos Medical, Inc. | 1 | $47 |
| Dexcom, Inc. | 3 | $42 |
| Amarin Pharma, Inc. | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $41 |
| Astellas Pharma US Inc | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| VBI Vaccine (delaware) Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| UCB, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$4,959 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $52,061 |
| MounjaroTirzepatide | 44 | $46,180 |
| JardianceEmpagliflozin | 40 | $45,468 |
| EliquisApixaban | 29 | $43,305 |
| OzempicSemaglutide | 34 | $35,764 |
| FarxigaDapagliflozin Propanediol | 26 | $17,970 |
| MyrbetriqMirabegron | 23 | $17,572 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $4,026 |
| Novolog FlexpenInsulin Aspart | 14 | $3,317 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,786 |
| Atorvastatin Calcium | 266 | $2,313 |
| Levemir FlexpenInsulin Detemir | 16 | $1,978 |
| Gabapentin | 57 | $1,552 |
| Potassium Chloride | 27 | $1,397 |
| Amlodipine Besylate | 219 | $1,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $262 | $52,06139 claims |
| Lilly USA, LLCMounjaro | $382 | $46,18044 claims |
| Boehringer IngelheimJardiance | $49 | $45,46840 claims |
| PfizerEliquis | $204 | $43,30529 claims |
| Novo NordiskOzempic | $722 | $35,76434 claims |
| AstraZenecaFarxiga, Symbicort | $369 | $21,99643 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $17,57223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Savannah
- Christopher OldfieldSavannah$6.4M
- Debbie HaginsSavannah$2.1M
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.